Shu-yuan Wang

发表

Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma

B. Han, Bo Jin, F. Qian, 2017, The Journal of thoracic and cardiovascular surgery.

Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy

B. Han, Xueyan Zhang, H. Zhong, 2019, Annals of Surgical Oncology.

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations

Bo Zhang, Bo Zhang, Shu-yuan Wang, 2021, Frontiers in Oncology.

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer

Xueyan Zhang, H. Zhong, Jun Lu, 2022, Frontiers in Pharmacology.

Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy

Xueyan Zhang, Hongfeng Yu, H. Zhong, 2022, Journal of translational medicine.

Local consolidative therapy for synchronous oligometastatic non‐small cell lung cancer treated with first‐line pembrolizumab: A retrospective observational study

Jun Lu, F. Qian, Shu-yuan Wang, 2022, Thoracic cancer.

Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells

B. Han, Xiaodong Zhao, Yu Dong, 2020, Acta Pharmacologica Sinica.

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

Kai Zhang, B. Han, Bing Li, 2022, BMC Medicine.

Advanced Non–Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy

B. Han, K. Gu, Midie Xu, 2020, Journal of immunotherapy.

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

B. Han, Xiaodong Zhao, Huimin Wang, 2019, Front. Oncol..

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation

B. Han, Ping Yang, K. Gu, 2021, Oncoimmunology.

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

Jun Lu, Wei Xu, Jie Qian, 2019, BMC Medical Genomics.

Adjuvant Chemotherapy Improves Survival in Surgically Resected Stage IB Squamous Lung Cancer.

B. Han, Xueyan Zhang, H. Zhong, 2019, The Annals of thoracic surgery.

Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations

P. Hu, Xueyan Zhang, Huimin Wang, 2019, Clinical lung cancer.

Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.

B. Han, R. Qiao, Rui Wang, 2018, Lung cancer.

Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion

B. Han, R. Qiao, F. Qian, 2018, The Journal of thoracic and cardiovascular surgery.

Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.

B. Han, K. Gu, Midie Xu, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab

B. Han, K. Gu, Midie Xu, 2020, Oncoimmunology.

Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies

B. Han, Yu Dong, H. Zhong, 2020, International journal of cancer.

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus

B. Han, Lin Wang, Jun Lu, 2021, Frontiers in Oncology.

Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas

B. Han, Jun Lu, R. Qiao, 2018, Cancer.

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

B. Han, Yu Dong, Hai Hu, 2021, Frontiers in Oncology.

Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis

B. Han, Shu-yuan Wang, Wei Zhang, 2020, Targeted Oncology.

Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.

B. Han, Yu Dong, Shu-yuan Wang, 2020, Clinical lung cancer.

Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation

B. Han, Yu Dong, Jun Lu, 2019, International journal of cancer.

Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib

B. Han, R. Qiao, Jianlin Xu, 2019, Targeted Oncology.

Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?

B. Han, Xueyan Zhang, Huimin Wang, 2018, Lung cancer.

Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma

B. Han, Jianlin Xu, Shu-yuan Wang, 2019, Molecular Diagnosis & Therapy.

Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.

B. Han, R. Qiao, Jianlin Xu, 2019, Clinical lung cancer.

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer

Y. Li, Xueyan Zhang, H. Zhong, 2023, Frontiers in Immunology.

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

B. Han, Xiaodong Zhao, W. Xu, 2019, BMC Medical Genomics.

Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review

B. Han, Xueyan Zhang, Jun Lu, 2018, Targeted Oncology.

Correction: Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

Xi Chen, Jun Lu, R. Qiao, 2022, BMC medical genomics.

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases

B. Han, R. Qiao, Y. Lou, 2019, Journal of Cardiothoracic Surgery.

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer

Y. Li, Xueyan Zhang, H. Zhong, 2023, Frontiers in Immunology.

Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways

Hong Yu, Shu-yuan Wang, Lei Zhu, 2023, Chinese medical journal.

PEG2000-PLA-based nanoscale polymeric micelles reduce paclitaxel-related toxicity in beagle dogs.

H. Zhong, Jun Lu, Y. Lou, 2023, Journal of controlled release : official journal of the Controlled Release Society.